Science · Иммунология

NKG2D: рецептор стресс-лигандов опухолей

Natural-killer receptor, binds MICA и MICB на stressed клетках. Recognition half NKG2D-LIF6 chimera.

Что такое NKG2D?

NKG2D (Natural-Killer Group 2, member D) — activating receptor, expressed на natural killer (NK) cells, γδ T cells и CD8+ T cells. Это часть immune system's tumor surveillance machinery — system, which patrols body для cells, которые look stressed, transformed или infected.

NKG2D recognizes set of ligands called MICA, MICB и ULBP1-6. Эти ligands fascinating, потому что absent or very low в healthy tissue. Появляются на surface клеток, когда клетка stressed — DNA damage, oxidative stress, heat shock, viral infection или malignant transformation. Когда NKG2D-bearing immune cell sees эти ligands, она triggers cytotoxic response: cell gets killed.

Это essentially universal "kill-me" signal, которое stressed cells display, и которое immune system has evolved to read.

Почему это relevant для онкологии

Solid tumor cells widely express MICA и MICB. Они stressed клетки — uncontrolled proliferation, DNA damage, metabolic stress all conspire upregulate these ligands. Это makes их visible immune system через NKG2D pathway.

Однако tumors evolved несколько escape mechanisms:

• Ligand shedding: Tumors cleave MICA/MICB and release soluble form, который binds NKG2D на NK cells далеко от tumor — decoy.
• NKG2D downregulation: Soluble MICA/MICB causes NKG2D internalization, reducing NK cells' ability respond.
• Immune exclusion: Tumors create microenvironment, который keeps NK cells out — physical barriers, chemokine gradients.

Как мы используем NKG2D

В NKG2D-LIF6 chimera, мы используем NKG2D extracellular domain (residues 79-216) как recognition module. Вместо connection к NK cell's intracellular signaling machinery, мы fused его к elephant LIF6 (effector module) через P2A linker.

Логика: bypass NK cells entirely. Constructed chimera expressed на surface tumor cell (после AAV9-mediated transduction) — когда NKG2D portion binds MICA/MICB ligands (which tumor cell itself expresses), LIF6 portion triggers apoptosis того же cell. Это essentially cell suicide signal, gated by tumor stress markers.

Healthy cells без MICA/MICB stay safe — chimera expressed, но has ничего bind. Tumor cells, expressing stress ligands, get triggered.

Clinical precedent

NKG2D-targeted therapies actively developed multiple companies. Fate Therapeutics' FT536 — NKG2D-CAR NK cell therapy currently в Phase I trials. Celularity и other companies pursuing подобные approaches. Field clinically validated в том смысле, что NKG2D-MICA/MICB axis is a real target. Pharmacology mostly through CAR-T or CAR-NK platforms — expensive, autologous, manufacturing-heavy.

Наше approach отличается: single AAV9-deliverable construct, integrated recognition + effector, без cell processing required.

Open questions

• Ligand shedding evasion: Если tumor sheds MICA/MICB to evade NK cells, will it also evade our chimera? Возможно но construct expressed внутри tumor cell — recognition local, не systemic.
• On-target/off-tumor: Какие healthy tissues могут transiently express MICA/MICB? Stressed tissues после injury, infection, autoimmune flares. Need to characterize.
• Off-target NK engagement: Если AAV9 transduces NK cells, и NK cell expresses NKG2D-LIF6 chimera, что происходит? NK cell already имеет NKG2D — это interfere?

Написано Артёмом Шакиным, founder Nightbox LLC. Published 2026-04-30. CC BY 4.0.